
First Faecal Microbiota Transplant (MRT) in Singapore performed by Dr. David Ong: AMILI Co-Founder.

Your gut is unique - and so is Asia. AMILI is one of the leading microbiome companies in the region, built on the world’s largest multi-ethnic Asian gut microbiome database. We use science made for Asia to create targeted products and services that support better gut health in everyday life.
Tracingourjourneyfromresearchoriginstoregionalimpact

First Faecal Microbiota Transplant (MRT) in Singapore performed by Dr. David Ong: AMILI Co-Founder.

Founding of AMILI.

Launched fist Southeast Asia's gut health test and MRT service.

Launched targeted probiotics for multi-ethnic asia.

Raised $10.5M USD Series A.

Introduced Analytics-as-a-service; Brand behind the Brands.

Prototyping of microbial test kits for colorectal cancer.

A*STAR partnership to personalise nutrition with the gut as the cornerstone; Diet-as-a-service offering in 2026.
Our strength lies in the passion and expertise of our team. Our diverse group of professionals brings together world-class experience in healthcare, research, and innovation.
Meet the leaders driving microbiome science forward at the helm:
CEO & CO-FOUNDER
CO-FOUNDER & VICE-CHAIRMAN
CO-FOUNDER
CO-FOUNDER
CHIEF OPERATING OFFICER
CHIEF GROWTH OFFICER
Professor Dr. Michael Kamm
Associate Professor Dr. Pises Pisespongsa
Adj. Associate Professor Dr. Reuben Wong
May Loh
Associate Professor Lee Yuan Kun
Professor Dr. Jose Sollano
Assistant Professor Dr. Ching Jianhong
Prem SamtaniStayupdatedwithAMILI'slatestbreakthroughsandmediahighlights.

body as a vibrant ecosystem, not just a single organism. Every day, trillions of tiny allies—bacteria, fungi, viruses,
ExploreopportunitiestogrowyourcareerwhilemakingameaningfulimpacthereatAMILI